+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now
global dermatology market

Recent Highs & Lows in the Vaccine Market 

14 January 2020
Pharma

global dermatology market

With the emergence of new health technology and advances in vaccines, manufacturers and key stakeholders can position themselves to generate big returns in the coming years. However, getting ahead of the competition will require having the right tools at your disposal, which is why Visiongain is proud to offer extensive vaccine market forecasts, as well as reports from other verticals like pharma, dermatology, and more. 

Below, we’ve compiled some of the latest market info and emerging trends for your perusal. 

Market Growth & Consolidation Factors 

The global vaccine market is experiencing rapid growth in several sectors, one of which is the Chinese market, where expanding immunization programs are calling for increased vaccines. As newly industrialized or lesser developed countries begin constructing more comprehensive vaccine and immunization technologies, there are a lot of opportunities for investors and drug developers to be at the forefront. 

Another lucrative area in the global vaccination market is creating vaccines for older individuals since many children have already received the most up-to-date vaccines. Disease prevention in both old and young can help create big improvements in the long-term since vaccinations are a fraction of the cost of treating actual diseases and chronic disorders. 

Vaccine Shortages & Other Industry Concerns 

One important thing to note in the years ahead is that, due to the success of vaccines, like those that treat polio, smallpox, and measles, there is actually a shortage of some vaccines. In a recent article on the subject, experts said it was “ironic,” stating that vaccines have done such a great job at reducing risks people often forget how necessary they are. Some of the most pressing vaccine shortages include that for varicella, the pneumococcal conjugate vaccine (PCV), which guards against pneumonia, meningitis, and ear infections, as well as tetanus vaccines. 

This leaves much room for growth, in particular the increased manufacturing of important vaccines for patients around the world. Some in the industry have called for changes in legislation that would enable animal testing when human testing isn’t possible as a solution. Other have proposed solutions to the shortage like added oversight, centralization, and accountability at the governmental level. 

Let Visiongain help you handle emerging trends in the vaccine market! 

Visiongain can provide you with the necessary information to make informed decisions in the coming years. We offer in-depth reports in the pharmaceutical and medical industry, everything from global dermatology market breakdowns to medical device forecasts, and more. 

For more than 20 years, the team from Visiongain has been helping key stakeholders in a variety of industries excel. With more than 1,500 reports across over 18 market verticals, it’s easy to find the insight you need. 

Call today at +44 (0) 20 7549 9987 or visit us online for more information. 

Recent News

Visiongain Publishes Drug Delivery Technologies Market Report 2024-2034

The global Drug Delivery Technologies market is estimated at US$1,729.6 billion in 2024 and is projected to grow at a CAGR of 5.5% during the forecast period 2024-2034.

23 April 2024

Read

Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034

The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.

18 April 2024

Read

Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034

The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.

17 April 2024

Read

Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034

The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.

12 April 2024

Read